Last reviewed · How we verify
Alcohol withdrawal delirium — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Valium | diazepam | Generic (originally Roche) | Benzodiazepine [EPC] | Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2 | 1963-11-15 | |
| Chlordiazepoxide Hydrochloride | CHLORDIAZEPOXIDE | Bausch Health | Benzodiazepine | Histamine H1 receptor | 1960-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bausch Health · 1 drug in Alcohol withdrawal delirium
- Generic (originally Roche) · 1 drug in Alcohol withdrawal delirium
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Alcohol withdrawal delirium:
- Alcohol withdrawal delirium treatment updates — RSS
- Alcohol withdrawal delirium treatment updates — Atom
- Alcohol withdrawal delirium treatment updates — JSON
Cite this brief
Drug Landscape (2026). Alcohol withdrawal delirium — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/alcohol-withdrawal-delirium. Accessed 2026-06-11.
Related
- Alcohol withdrawal delirium full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing